Literature DB >> 19364870

Combination of daptomycin plus ceftriaxone is more active than vancomycin plus ceftriaxone in experimental meningitis after addition of dexamethasone.

U Egermann1, Z Stanga, A Ramin, F Acosta, A Stucki, P Gerber, M Cottagnoud, P Cottagnoud.   

Abstract

We examined the cerebrospinal fluid penetration of daptomycin after the addition of dexamethasone and its bactericidal efficacy with and without ceftriaxone in an experimental rabbit model of pneumococcal meningitis. The combination of daptomycin with ceftriaxone was the most efficacious regimen for pneumococcal meningitis. The previous addition of dexamethasone affected the antibacterial activity of daptomycin only marginally, either as monotherapy or combined with ceftriaxone, although the penetration of daptomycin into inflamed meninges was significantly reduced from 6 to 2%. Daptomycin with ceftriaxone might be a potential candidate for the empirical therapy of bacterial meningitis, although the activity of this regimen against Listeria monocytogenes remains to be demonstrated.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19364870      PMCID: PMC2704679          DOI: 10.1128/AAC.00952-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999.

Authors:  D J Hoban; G V Doern; A C Fluit; M Roussel-Delvallez; R N Jones
Journal:  Clin Infect Dis       Date:  2001-05-15       Impact factor: 9.079

2.  Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis.

Authors:  Denis Grandgirard; Christian Schürch; Philippe Cottagnoud; Stephen L Leib
Journal:  Antimicrob Agents Chemother       Date:  2007-03-19       Impact factor: 5.191

3.  Community-acquired bacterial meningitis in adults: categorization of causes and timing of death.

Authors:  D A McMillan; C Y Lin; S I Aronin; V J Quagliarello
Journal:  Clin Infect Dis       Date:  2001-08-22       Impact factor: 9.079

4.  Daptomycin is more efficacious than vancomycin against a methicillin-susceptible Staphylococcus aureus in experimental meningitis.

Authors:  Peter Gerber; Armin Stucki; Fernando Acosta; Marianne Cottagnoud; Philippe Cottagnoud
Journal:  J Antimicrob Chemother       Date:  2006-02-03       Impact factor: 5.790

5.  Experimental study of the efficacy of vancomycin, rifampicin and dexamethasone in the therapy of pneumococcal meningitis.

Authors:  J Martínez-Lacasa; C Cabellos; A Martos; A Fernández; F Tubau; P F Viladrich; J Liñares; F Gudiol
Journal:  J Antimicrob Chemother       Date:  2002-03       Impact factor: 5.790

6.  Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis.

Authors:  Philippe Cottagnoud; Marc Pfister; Fernando Acosta; Marianne Cottagnoud; Lukas Flatz; Felix Kühn; Hans-Peter Müller; Armin Stucki
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

Review 7.  Daptomycin: a new treatment for insidious infections due to gram-positive pathogens.

Authors:  Philippe Cottagnoud
Journal:  Swiss Med Wkly       Date:  2008-02-23       Impact factor: 2.193

8.  Effect of dexamethasone on therapy of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis.

Authors:  M M París; S M Hickey; M I Uscher; S Shelton; K D Olsen; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

9.  Effect of probenecid on cerebrospinal fluid concentrations of penicillin and cephalosporin derivatives.

Authors:  R G Dacey; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1974-10       Impact factor: 5.191

10.  Emergence of multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999-2003).

Authors:  David M Johnson; Matthew G Stilwell; Thomas R Fritsche; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2006-03-20       Impact factor: 2.803

View more
  5 in total

1.  Adjunctive daptomycin attenuates brain damage and hearing loss more efficiently than rifampin in infant rat pneumococcal meningitis.

Authors:  Denis Grandgirard; Melchior Burri; Philipp Agyeman; Stephen L Leib
Journal:  Antimicrob Agents Chemother       Date:  2012-05-29       Impact factor: 5.191

Review 2.  Pathogenesis and pathophysiology of pneumococcal meningitis.

Authors:  Barry B Mook-Kanamori; Madelijn Geldhoff; Tom van der Poll; Diederik van de Beek
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

3.  Combination therapy with daptomycin, linezolid, and rifampin as treatment option for MRSA meningitis and bacteremia.

Authors:  Theodoros Kelesidis; Romney Humphries; Kevin Ward; Michael A Lewinski; Otto O Yang
Journal:  Diagn Microbiol Infect Dis       Date:  2011-08-19       Impact factor: 2.803

4.  Pharmacokinetics of single-dose daptomycin in patients with suspected or confirmed neurological infections.

Authors:  Ravina Kullar; Judy N Chin; David J Edwards; Dennis Parker; William M Coplin; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2011-04-18       Impact factor: 5.191

5.  Attenuation of cerebrospinal fluid inflammation by the nonbacteriolytic antibiotic daptomycin versus that by ceftriaxone in experimental pneumococcal meningitis.

Authors:  Denis Grandgirard; Kevin Oberson; Angela Bühlmann; Rahel Gäumann; Stephen L Leib
Journal:  Antimicrob Agents Chemother       Date:  2010-01-11       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.